Lilly Restructuring Positions Leichleiter As Heir Apparent To CEO Taurel
Executive Summary
Lilly's promotion of John Leichleiter to president and chief operating officer positions him as the likely successor to CEO Sidney Taurel
You may also be interested in...
Lilly restructuring (correction)
Lilly Exec VP-Science & Technology Steve Paul reports to CEO Sidney Taurel. In a story on Lilly's restructuring, "The Pink Sheet" incorrectly stated that Paul reports to President & Chief Operating Officer John Lechleiter (1"The Pink Sheet" Sept. 26, 2005, p. 19)...
Lilly restructuring (correction)
Lilly Exec VP-Science & Technology Steve Paul reports to CEO Sidney Taurel. In a story on Lilly's restructuring, "The Pink Sheet" incorrectly stated that Paul reports to President & Chief Operating Officer John Lechleiter (1"The Pink Sheet" Sept. 26, 2005, p. 19)...
Zyprexa Patent Valid: Lilly’s Phase I Olanzapine Trials Were Not “Public Use”
Lilly's conduct of Phase I clinical trials for Zyprexa prior to applying for a composition/use patent did not constitute a prior "public use" that would render the patent invalid, an Indianapolis federal judge ruled April 14